RELB

From Wikipedia, the free encyclopedia


V-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (avian)
PDB rendering based on 1zk9.
Available structures: 1zk9, 1zka
Identifiers
Symbol(s) RELB; I-REL
External IDs OMIM: 604758 MGI: 103289 HomoloGene: 4747
RNA expression pattern

More reference expression data
Orthologs
Human Mouse
Entrez 5971 19698
Ensembl ENSG00000104856 ENSMUSG00000002983
Uniprot Q01201 Q3U0K7
Refseq NM_006509 (mRNA)
NP_006500 (protein)		 NM_009046 (mRNA)
NP_033072 (protein)
Location Chr 19: 50.2 - 50.23 Mb Chr 7: 18.76 - 18.79 Mb
Pubmed search [1] [2]

V-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (avian), also known as RELB, is a human gene.


[edit] See also

[edit] Further reading

  • Taylor JP, Pomerantz R, Bagasra O, et al. (1992). "TAR-independent transactivation by Tat in cells derived from the CNS: a novel mechanism of HIV-1 gene regulation.". EMBO J. 11 (9): 3395–403. PMID 1505523. 
  • Bours V, Burd PR, Brown K, et al. (1992). "A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site.". Mol. Cell. Biol. 12 (2): 685–95. PMID 1531086. 
  • Ruben SM, Klement JF, Coleman TA, et al. (1992). "I-Rel: a novel rel-related protein that inhibits NF-kappa B transcriptional activity.". Genes Dev. 6 (5): 745–60. PMID 1577270. 
  • Liu J, Perkins ND, Schmid RM, Nabel GJ (1992). "Specific NF-kappa B subunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription.". J. Virol. 66 (6): 3883–7. PMID 1583734. 
  • Biswas DK, Salas TR, Wang F, et al. (1996). "A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter.". J. Virol. 69 (12): 7437–44. PMID 7494249. 
  • Jeang KT, Chun R, Lin NH, et al. (1993). "In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor.". J. Virol. 67 (10): 6224–33. PMID 7690421. 
  • Alcamí J, Laín de Lera T, Folgueira L, et al. (1995). "Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes.". EMBO J. 14 (7): 1552–60. PMID 7729429. 
  • Majello B, De Luca P, Hagen G, et al. (1995). "Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1.". Nucleic Acids Res. 22 (23): 4914–21. PMID 7800480. 
  • Taylor JP, Pomerantz RJ, Oakes JW, et al. (1995). "A CNS-enriched factor that binds to NF-kappa B and is required for interaction with HIV-1 tat.". Oncogene 10 (2): 395–400. PMID 7838536. 
  • Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al. (1995). "HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state.". EMBO J. 14 (3): 546–54. PMID 7859743. 
  • Scala G, Ruocco MR, Ambrosino C, et al. (1994). "The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein.". J. Exp. Med. 179 (3): 961–71. PMID 8113688. 
  • Bours V, Azarenko V, Dejardin E, Siebenlist U (1994). "Human RelB (I-Rel) functions as a kappa B site-dependent transactivating member of the family of Rel-related proteins.". Oncogene 9 (6): 1699–702. PMID 8183565. 
  • Deloukas P, Dauwerse JG, van Ommen GJ, van Loon AP (1994). "The human NFKB3 gene encoding the p65 subunit of transcription factor NF-kappa B is located on chromosome 11q12.". Genomics 19 (3): 592–4. doi:10.1006/geno.1994.1115. PMID 8188306. 
  • Westendorp MO, Li-Weber M, Frank RW, Krammer PH (1994). "Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells.". J. Virol. 68 (7): 4177–85. PMID 8207793. 
  • Dobrzanski P, Ryseck RP, Bravo R (1993). "Both N- and C-terminal domains of RelB are required for full transactivation: role of the N-terminal leucine zipper-like motif.". Mol. Cell. Biol. 13 (3): 1572–82. PMID 8441398. 
  • Harhaj E, Blaney J, Millhouse S, Sun SC (1996). "Differential effects of I kappa B molecules on Tat-mediated transactivation of HIV-1 LTR.". Virology 216 (1): 284–7. doi:10.1006/viro.1996.0062. PMID 8615004. 
  • Conant K, Ma M, Nath A, Major EO (1996). "Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-kappa B binding and protein kinase C activity in primary human astrocytes.". J. Virol. 70 (3): 1384–9. PMID 8627654. 
  • Demarchi F, d'Adda di Fagagna F, Falaschi A, Giacca M (1996). "Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1.". J. Virol. 70 (7): 4427–37. PMID 8676466. 
  • Beauparlant P, Kwon H, Clarke M, et al. (1996). "Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.". J. Virol. 70 (9): 5777–85. PMID 8709193. 
  • Ramazzotti E, Vignoli M, Re MC, et al. (1996). "Enhanced nuclear factor-kappa B activation induced by tumour necrosis factor-alpha in stably tat-transfected cells is associated with the presence of cell-surface-bound Tat protein.". AIDS 10 (5): 455–61. PMID 8724035. 
 This article on a gene on chromosome 19 is a stub. You can help Wikipedia by expanding it.
v • d • e
Transcription factors and intracellular receptors
(1) Basic domains
(1.1) Basic leucine zipper (bZIP)
Activating transcription factor (AATF, 1, 2, 3, 4, 5, 6, 7) • AP-1 (c-Fos, FOSB, FOSL1, FOSL2, c-Jun, JUNB, JUND) • BACH (1, 2) • BATF • BLZF1 • C/EBP (α, β, γ, δ, ε, ζ) • CREB (1, 3, L1) • CREM • DBP • DDIT3 • GABPA • HLF • MAF (B, F, G, K) • NFE (2, L1, L2) • NRL • NRF1 • XBP1
(1.2) Basic helix-loop-helix (bHLH)
ATOH1 • AhR • AHRR • ARNT • ASCL1 • BHLHB2 • BMAL (ARNTL, ARNTL2) • CLOCK • EPAS1 • HAND (1, 2) • HES (5, 6) • HEY (1, 2, L) • HES1 • HIF (1A, 3A) • ID (1, 2, 3, 4) • LYL1 • MXD4 • MYCL1 • MYCN • Myogenic regulatory factors (MyoD, Myogenin, MYF5, MYF6) • Neurogenins • NeuroD (1, 2) • NPAS (1, 2, 3) • OLIG (1, 2) • Scleraxis • TAL1 • Twist • USF1
(1.3) bHLH-ZIP
MAX • MITF • MNT • MLX • MXI1 • Myc • SREBP (1, 2)
(1.6) Basic helix-span-helix (bHSH)
(2) Zinc finger
DNA-binding domains
(2.1) Nuclear receptor (Cys4)
subfamily 1 (Thyroid hormone (α, β), CAR, FXR, LXR (α, β), PPAR (α, β/δ, γ), PXR, RAR (α, β, γ), ROR (α, β, γ), Rev-ErbA (α, β), VDR) • subfamily 2 (COUP-TF (I, II), Ear-2, HNF4 (α, γ), PNR, RXR (α, β, γ), Testicular receptor (2, 4), TLX) • subfamily 3 (Steroid hormone (Estrogen (α, β), Estrogen related (α, β, γ), Androgen, Glucocorticoid, Mineralocorticoid, Progesterone)) • subfamily 4 NUR (NGFIB, NOR1, NURR1) • subfamily 5 (LRH-1, SF1) • subfamily 6 (GCNF) • subfamily 0 (DAX1, SHP)
(2.2) Other Cys4
GATA (1, 2, 3, 4, 5, 6) • MTA (1, 2, 3)
(2.3) Cys2His2
ATBF1 • BCL(6, 11A, 11B) • CTCF • E4F1 • EGR (2, 3) • ERV3 • General transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF: 1, 2, TFIIH: 1, 2, 4, 2I, 3A, 3C1, 3C2) • GFI1 • GLI-Krüppel family (1, 2, 3, YY1) • HIC (1, 2) • HIVEP (1, 2, 3) • IKZF (1, 2, 3) • ILF (2, 3) • KLF (2, 4, 5, 6, 9, 10, 11, 12, 13) • MTF1 • MYT1 • OSR1 • Sp1 • zinc finger ((3, 7, 9, 10, 19, 22, 24, 33B, 34, 35, 41, 43, 44, 51, 74, 143, 146, 148, 165, 202, 217, 219, 238, 239, 259, 267, 268, 281, 295, 318, 330, 346, 350, 365, 366, 384, 451, 452, 471, 593, 638, 649, 655) • Zbtb7 (7A) • ZBT (16, 17, 33)
(2.4) Cys6
(2.5) Alternating composition
AIRE • DIDO1 • GRLF1 • ING (1, 2, 4) • JARID (1A, 1B, 1C, 1D, 2) • JMJD1B
(3) Helix-turn-helix
domains
ARX • CDX (1, 2) • CRX • CUTL1 • DLX (3, 4, 5) • EMX2 • EN (1, 2) • FHL (1, 2, 3) • HESX1 • HHEX • HLX • Homeobox (A1, A3, A4, A5, A7, A9, A10, A11, A13, B1, B2, B3, B4, B5, B6, B7, B8, B9, B13, C4, C5, C6, C8, C9, C10, C11, C13, D1, D3, D4, D8, D9, D10, D11, D12, D13) • HOPX • MEIS (1, 2) • MEOX2 • MNX1 • MSX (1, 2) • NANOG • NKX (2-1, 2-5, 3-1) • PHF (3, 6, 10, 17) • POU domain (PIT-1, BRN-3: 1, 2, Octamer transcription factor: 1, 2, 3/4, 6, 7) • OTX (1, 2) • PDX1
(3.2) Paired box
PAX (1, 2, 3, 4, 5, 6, 7, 8, 9)
E2F (1, 2, 3, 4, 5) • FOX proteins (C1, C2, E1, G1, H1, K2, L2, M1, N3, O1A, , O3A, O4, P1, P2, P3)
HSF (1, 2, 4)
(3.5) Tryptophan clusters
ELF (4, 5) • EGF • ELK (1, 3, 4) • ERF • ERG • ETS (1, 2) • ETV (1, 4, 5, 6) • FLI1 • Interferon regulatory factors (1, 2, 3, 4, 5, 6, 7, 8) • MYB • MYBL2
(3.6) TEA domain
transcriptional enhancer factor 1, 2
(4) β-Scaffold factors with
minor groove contacts
(4.1) Rel homology region
NF-κB (NFKB1, NFKB2, REL, RELA, RELB) • NFAT (C1, C2, C3, C4, 5)
(4.2) STAT
STAT (1, 2, 3, 4, 5, 6)
(4.3) p53
(4.4) MADS box
Mef2 (A, B, C, D) • SRF
HNF (1A, 1B) • LEF1 • SOX (2, 3, 4, 5, 6, 8, 9, 10, 11, 13, 15, 18) • SRY • SSRP1
(4.10) Cold-shock domain
(4.11) Runt
(0) Other
transcription factors
(0.2) HMGI(Y)
HMGA (1, 2) • HBP1
Rb • RBL1 • RBL2
(0.5) AP-2/EREBP-related factors
Apetala 2 • EREBP • B3
(0.6) Miscellaneous
ARID (1A, 1B, 2, 3A, 3B, 4A) • CAP • IFI (16, 35) • MLL (2, 3, T1) • MNDA • NFI (A, B, C, X) • NFY (A, B, C) • Rho/Sigma • R-SMAD